Advertisement

Reactions Weekly

, Volume 1753, Issue 1, pp 262–262 | Cite as

Nivolumab/osimertinib

Interstitial lung diseases: 3 case reports
Case report
  • 4 Downloads

Reference

  1. Uchida T, et al. Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer. Thoracic Cancer 10: 975-979, No. 4, Apr 2019. Available from: URL: http://doi.org/10.1111/1759-7714.13039 - Japan

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations